Background
Prespecified BM subgroup analysis of HER2CLIMB, a phase III double-blind RCT, N=612 (410 tucatinib, 202 placebo; 2:1), HER2+ metastatic breast cancer after trastuzumab, pertuzumab, and T-DM1. Tucatinib (selective HER2 TKI) + trastuzumab + capecitabine vs placebo + trastuzumab + capecitabine. BM subgroup n=291 (198 tucatinib, 93 placebo); active untreated, stable, and previously treated BM all eligible.
Interventions and follow up
Arm A: Tucatinib 300 mg PO BID + trastuzumab + capecitabine 1000 mg/m² PO BID days 1-14 q21d
Arm B: Placebo + trastuzumab + capecitabine
Primary endpoint: CNS PFS and OS in BM subgroup; secondary intracranial/extracranial ORR
mFollow up: 14.0 months (primary analysis)
Arm B: Placebo + trastuzumab + capecitabine
Primary endpoint: CNS PFS and OS in BM subgroup; secondary intracranial/extracranial ORR
mFollow up: 14.0 months (primary analysis)
Results
1-yr CNS PFS (BM subgroup): 40.2% vs 0%, HR 0.32, 95% CI 0.22-0.48, P<.0001
mOS (BM subgroup): 18.1 vs 12.0 months, HR 0.58, 95% CI 0.40-0.85, P=.005
Intracranial ORR (active BM): 47.3% vs 20.0%
Overall mPFS: 7.8 vs 5.6 months, HR 0.54, P<.001
Overall mOS: 24.7 vs 19.2 months, HR 0.66, P=.005
mOS (BM subgroup): 18.1 vs 12.0 months, HR 0.58, 95% CI 0.40-0.85, P=.005
Intracranial ORR (active BM): 47.3% vs 20.0%
Overall mPFS: 7.8 vs 5.6 months, HR 0.54, P<.001
Overall mOS: 24.7 vs 19.2 months, HR 0.66, P=.005
Adverse events
Grade ≥3 AEs: 55.6% vs 48.7%
Diarrhea Grade ≥3: 12.9% vs 8.6%
Hand-foot syndrome Grade ≥3: 13.2% vs 9.1%
ALT/AST elevation Grade ≥3: 5.1% vs 2.5%
Discontinuation due to AE: 5.7% vs 3.0%
Diarrhea Grade ≥3: 12.9% vs 8.6%
Hand-foot syndrome Grade ≥3: 13.2% vs 9.1%
ALT/AST elevation Grade ≥3: 5.1% vs 2.5%
Discontinuation due to AE: 5.7% vs 3.0%
Conclusions
Adding tucatinib reduced CNS progression risk by 68% (HR 0.32) and improved OS by 6.1 months (HR 0.58, P=.005) in HER2+ MBC with brain metastases, the first systemic regimen to show a significant OS benefit specifically in this population and the standard of care for this setting.
Key Limitations
Prespecified subgroup, not a standalone BM-primary trial; heterogeneous BM population (stable, active untreated, progressing); 2:1 randomization limits subgroup power; tucatinib + capecitabine diarrhea requires dose-reduction protocols; median follow-up of 14 months short for OS; no comparison to T-DXd, whose CNS data (DESTINY-Breast12, 12-month CNS PFS 61.6%) are competitive.
Clinical Context
HER2CLIMB led to FDA approval (April 2020) of tucatinib + trastuzumab + capecitabine for HER2+ MBC including patients with BM, the first systemic regimen shown to improve OS in HER2+ MBC with BM; ESMO endorses it for this setting. The subsequent DESTINY-Breast12 trial (T-DXd, 2024) showed 12-month CNS PFS 61.6% in BM patients, positioning T-DXd as a competitive or preferred option after trastuzumab + pertuzumab exposure. Optimal sequencing of tucatinib-combination vs T-DXd is evolving. Neratinib + capecitabine also has CNS activity (NALA); lapatinib is less effective.
References